Birchview Capital, LP Coherus Bio Sciences, Inc. Transaction History
Birchview Capital, LP
- $117 Million
- Q4 2024
A detailed history of Birchview Capital, LP transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 82,000 shares of CHRS stock, worth $79,540. This represents 0.1% of its overall portfolio holdings.
Number of Shares
82,000
Previous 372,000
77.96%
Holding current value
$79,540
Previous $386,000
70.73%
% of portfolio
0.1%
Previous 0.36%
Shares
3 transactions
Others Institutions Holding CHRS
# of Institutions
130Shares Held
67.8MCall Options Held
1.68MPut Options Held
91.8K-
Black Rock Inc. New York, NY11.8MShares$11.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$10.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$5.12 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$5.1 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$3.54 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $75.4M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...